CO5540293A2 - Composicion farmaceutica que comprende un inhibidor de lipasa y un ester de acido graso de sacarosa - Google Patents

Composicion farmaceutica que comprende un inhibidor de lipasa y un ester de acido graso de sacarosa

Info

Publication number
CO5540293A2
CO5540293A2 CO03106075A CO03106075A CO5540293A2 CO 5540293 A2 CO5540293 A2 CO 5540293A2 CO 03106075 A CO03106075 A CO 03106075A CO 03106075 A CO03106075 A CO 03106075A CO 5540293 A2 CO5540293 A2 CO 5540293A2
Authority
CO
Colombia
Prior art keywords
acid ester
lipase inhibitor
pharmaceutical composition
sacarose
fat acid
Prior art date
Application number
CO03106075A
Other languages
English (en)
Inventor
Karsten Maeder
Eugen Martin Rainer
Susanne Raab
Lukas Christoph Scheibler
Thomas Schindler
Marco Schroeder
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177654&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5540293(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5540293A2 publication Critical patent/CO5540293A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1.- Una composición farmacéutica que comprende un inhibidor de lipasas con un punto de fusión = 37°C, un éster de ácido graso de sacarosa en donde el éster de ácido graso de sacarosa es un mono-, di-, tri- o tetra-éster, y opcionalmente uno o más excipientes farmacéuticamente aceptables.36.- Un equipo para el tratamiento de obesidad, donde dicho equipo comprende un primer componente que es un inhibidor de lipasas y un segundo componente que es un éster de ácido graso de sacarosa en una forma de dosis unitaria.
CO03106075A 2001-06-06 2003-12-02 Composicion farmaceutica que comprende un inhibidor de lipasa y un ester de acido graso de sacarosa CO5540293A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01113793 2001-06-06

Publications (1)

Publication Number Publication Date
CO5540293A2 true CO5540293A2 (es) 2005-07-29

Family

ID=8177654

Family Applications (1)

Application Number Title Priority Date Filing Date
CO03106075A CO5540293A2 (es) 2001-06-06 2003-12-02 Composicion farmaceutica que comprende un inhibidor de lipasa y un ester de acido graso de sacarosa

Country Status (40)

Country Link
US (4) US20030027786A1 (es)
EP (1) EP1399152B1 (es)
JP (2) JP4261337B2 (es)
KR (1) KR100753729B1 (es)
CN (1) CN1514725B (es)
AR (1) AR034355A1 (es)
AT (1) ATE356622T1 (es)
AU (1) AU2002257817B2 (es)
BG (1) BG66346B1 (es)
BR (1) BRPI0210266B1 (es)
CA (1) CA2448030C (es)
CO (1) CO5540293A2 (es)
CY (1) CY1107641T1 (es)
CZ (1) CZ299948B6 (es)
DE (1) DE60218845T2 (es)
DK (1) DK1399152T3 (es)
EC (1) ECSP034871A (es)
ES (1) ES2282415T3 (es)
GT (1) GT200200106A (es)
HK (1) HK1067312A1 (es)
HR (1) HRP20030983B1 (es)
HU (1) HU230405B1 (es)
IL (2) IL158908A0 (es)
JO (1) JO2455B1 (es)
MA (1) MA27031A1 (es)
ME (1) ME00579B (es)
MX (1) MXPA03011191A (es)
MY (1) MY161871A (es)
NO (1) NO328006B1 (es)
NZ (1) NZ529630A (es)
PA (1) PA8546701A1 (es)
PE (1) PE20030230A1 (es)
PL (1) PL215266B1 (es)
PT (1) PT1399152E (es)
RS (1) RS50713B (es)
RU (1) RU2271808C2 (es)
SI (1) SI1399152T1 (es)
SK (1) SK287602B6 (es)
WO (1) WO2002098412A1 (es)
ZA (1) ZA200309007B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
FI20045076A (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
KR100910000B1 (ko) * 2005-05-13 2009-07-29 씨제이제일제당 (주) 리파아제 저해제 함유 약학 조성물
WO2006132440A1 (ja) * 2005-06-09 2006-12-14 Takeda Pharmaceutical Company Limited 固形製剤
US20070111914A1 (en) * 2005-11-16 2007-05-17 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Environmentally friendly laundry method and kit
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
EP1872777A1 (en) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising tetrahydrolipstatin
GB0618725D0 (en) * 2006-09-23 2006-11-01 Jagotec Ag Composition containing inhibitors of gastro-intestinal lipase
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
US8309107B2 (en) * 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
FR2994386B1 (fr) * 2012-08-07 2016-06-24 Thorel Jean-Noel Inhibition de l'adhesion de micro-organismes pathogenes par un ester de saccharose et/ou de sorbitan dans le traitement cosmetique de l'atopie cutanee
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
CN104546768B (zh) * 2014-12-30 2017-06-16 重庆植恩药业有限公司 含有脂肪酶抑制剂的咀嚼片组合物及其制备方法
MA45430A (fr) 2015-10-23 2019-05-01 Erx Pharmaceuticals Inc Analogues de célastrol
CN113151373B (zh) * 2021-03-09 2023-07-04 武汉臻治生物科技有限公司 一种具有抗菌及抗肿瘤活性的蔗糖单酯的制备方法及其应用
KR102637596B1 (ko) 2022-03-18 2024-02-19 (주)보노보씨 기능성 목공교구

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1965133A1 (de) 1969-12-27 1971-07-22 Merck Patent Gmbh Verfahren zur Herstellung pharmazeutischer Zubereitungen
US4148924A (en) * 1977-06-13 1979-04-10 The Procter & Gamble Company Dermatological compositions
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
NL8600050A (nl) 1986-01-13 1987-08-03 Sanico Nv Farmaceutisch preparaat met vertraagde afgifte van het werkzame bestanddeel en werkwijze voor de bereiding er van.
EP0271963B1 (en) * 1986-12-19 1993-07-21 The Procter & Gamble Company Food compositions with superior blood cholesterol lowering properties
JP2748597B2 (ja) 1989-09-28 1998-05-06 三菱化学株式会社 食品劣化抑制剤
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
JP3112473B2 (ja) 1990-10-18 2000-11-27 オリンパス光学工業株式会社 屈折率分布型光学素子の製造方法
US5294451A (en) * 1991-03-29 1994-03-15 Curtice-Burns, Inc. Fat substitute compositions having reduced laxative effects
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
FR2735658B1 (fr) * 1995-06-21 1997-09-12 Capsulis Encapsulation de composes a usage alimentaire par des tensioactifs
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
CA2340052C (en) 1998-08-14 2007-05-29 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors and chitosan
AU761351B2 (en) 1998-08-14 2003-06-05 Cheplapharm Arzneimittel Gmbh Pharmaceutical compositions containing lipase inhibitors
AU1031500A (en) 1998-11-03 2000-05-22 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
US6348492B1 (en) 1999-10-29 2002-02-19 2Pro Chemical Oxetanone derivatives
AU1347701A (en) 1999-10-29 2001-05-14 John Jason Gentry Mullins Oxetanone derivatives
JP4149803B2 (ja) * 2000-06-27 2008-09-17 エフ．ホフマン−ラ ロシュ アーゲー 組成物の調製方法
BR0112800A (pt) 2000-07-28 2003-07-01 Hoffmann La Roche Utilização de um inibidor de lìpases e de um sequestrante de ácido de bìlis farmaceuticamente aceitáveis e processo para a prevenção e tratamento de enfermidades associadas com altos nìveis de colesterol de plasma
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6534097B1 (en) * 2002-07-11 2003-03-18 Betty Baggott Pest repellent

Also Published As

Publication number Publication date
HUP0401208A3 (en) 2008-04-28
BG66346B1 (bg) 2013-08-30
JP2004532271A (ja) 2004-10-21
SK16092003A3 (sk) 2004-05-04
ES2282415T3 (es) 2007-10-16
NZ529630A (en) 2006-05-26
EP1399152A1 (en) 2004-03-24
NO20035318D0 (no) 2003-11-28
MA27031A1 (fr) 2004-12-20
KR20040010689A (ko) 2004-01-31
NO328006B1 (no) 2009-11-09
CN1514725B (zh) 2010-04-21
US20130079391A1 (en) 2013-03-28
EP1399152B1 (en) 2007-03-14
PA8546701A1 (es) 2003-01-24
HRP20030983A2 (en) 2005-08-31
DE60218845T2 (de) 2008-01-03
KR100753729B1 (ko) 2007-08-30
CA2448030C (en) 2009-11-24
US20050101562A1 (en) 2005-05-12
IL158908A (en) 2008-08-07
BR0210266A (pt) 2004-07-20
HUP0401208A2 (hu) 2004-11-29
PT1399152E (pt) 2007-06-05
US20110301231A1 (en) 2011-12-08
MXPA03011191A (es) 2004-02-26
MY161871A (en) 2017-05-15
GT200200106A (es) 2003-02-11
JO2455B1 (en) 2008-10-09
AU2002257817B2 (en) 2005-08-18
BRPI0210266B1 (pt) 2016-01-26
SK287602B6 (sk) 2011-03-04
HK1067312A1 (en) 2005-04-08
ME00579A (en) 2011-12-20
CA2448030A1 (en) 2002-12-12
US20030027786A1 (en) 2003-02-06
WO2002098412A1 (en) 2002-12-12
US8039508B2 (en) 2011-10-18
PE20030230A1 (es) 2003-03-17
IL158908A0 (en) 2004-05-12
AR034355A1 (es) 2004-02-18
JP2009108076A (ja) 2009-05-21
RS96003A (en) 2006-10-27
HRP20030983B1 (en) 2011-10-31
CZ20033525A3 (cs) 2004-04-14
DE60218845D1 (de) 2007-04-26
RU2271808C2 (ru) 2006-03-20
ECSP034871A (es) 2004-01-28
ME00579B (me) 2011-12-20
RS50713B (sr) 2010-06-30
SI1399152T1 (sl) 2007-08-31
JP4261337B2 (ja) 2009-04-30
PL215266B1 (pl) 2013-11-29
HU230405B1 (hu) 2016-04-28
ZA200309007B (en) 2005-04-26
PL366890A1 (en) 2005-02-07
CY1107641T1 (el) 2013-04-18
CZ299948B6 (cs) 2009-01-07
CN1514725A (zh) 2004-07-21
DK1399152T3 (da) 2007-06-18
RU2003136728A (ru) 2005-05-20
US8343543B2 (en) 2013-01-01
ATE356622T1 (de) 2007-04-15
BG108421A (en) 2005-02-28

Similar Documents

Publication Publication Date Title
CO5540293A2 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y un ester de acido graso de sacarosa
CL2021003222A1 (es) (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.
AR063098A1 (es) Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
AR023228A1 (es) Composiciones en espuma estables
PA8481401A1 (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino
CR9808A (es) Procedimiento de tratamiento de la arterosclerosis, dispilidemias y afecciones relacionadas y composiciones farmaceuticas
BR9809793A (pt) Monoésteres de probucol para o tratamento de doença inflamatória e cardiovascular
CR6210A (es) Composiciones de celecoxib
CO5680108A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
HN2008001666A (es) Derivados acidos de cicloalquilamino
ES2167609T3 (es) Formulaciones de quinolona inyectables.
HN2002000198A (es) Composiciones farmaceuticas de amlodipina y atorvastatina
UY28097A1 (es) Activadores de ppar
DK1820506T3 (da) Dipyridamol-formuleringer med forlænget frigivelse og fremgangsmåde til fremstilling heraf
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
BR0213181A (pt) Combinações de inibidor de cox-2
CL2007002315A1 (es) Compuestos derivados de piridina;composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades o trastornos que comprenden el dolor y/o sindrome del intestino irritable.
CL2004001422A1 (es) Composicion farmaceutica que comprende un analgesico opioide y un compuesto derivado de 1-piperidinilpiperazina; su uso para la prevencion y/o tratamiento del dolor y nocicepcion, y para las nauseas y vomitos, en tratamientos de base opioide para el
UY30557A1 (es) Tratamiento y prevencion de la fibrosis intestinal
CL2021000627A1 (es) Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular
AR049143A1 (es) Composiciones farmaceuticas de interferon beta (ifn beta) para tratamiento de la miocardiopatia y la disfuncion endotelial
UY27321A1 (es) Nueva composición farmacéutica
CO5580753A2 (es) Composicion farmaceutica que comprende un antagonista ltb4 y un inhibidor cox-2 o un inhibidor cox1/2
BR0308871A (pt) Composição farmacêutica

Legal Events

Date Code Title Description
FG Application granted